| 1 |
34897998 | BoxCar and shotgun proteomic analyses reveal molecular networks regulated by UBR5 in prostate cancer. | 2022 Feb |
1 |
| 2 |
35051747 | Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. | 2022 Feb 15 |
1 |
| 3 |
35078817 | ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib. | 2022 Mar 15 |
2 |
| 4 |
35169388 | Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. | 2022 Feb |
1 |
| 5 |
35200549 | An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer. | 2022 Jan 27 |
1 |
| 6 |
35326611 | Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263. | 2022 Mar 12 |
1 |
| 7 |
35568265 | The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. | 2022 Aug 1 |
1 |
| 8 |
33012578 | Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. | 2021 Apr |
3 |
| 9 |
33091613 | Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer. | 2021 Feb 3 |
1 |
| 10 |
33660437 | WNT inhibition creates a BRCA-like state in Wnt-addicted cancer. | 2021 Apr 9 |
1 |
| 11 |
33722420 | Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? | 2021 Jun |
1 |
| 12 |
33722571 | PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. | 2021 Jun |
1 |
| 13 |
33742189 | Resistance to second-generation androgen receptor antagonists in prostate cancer. | 2021 Apr |
1 |
| 14 |
33984694 | PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice. | 2021 Aug |
1 |
| 15 |
34070674 | Breast Cancer Predisposition Genes and Synthetic Lethality. | 2021 May 25 |
1 |
| 16 |
34082024 | ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. | 2021 Sep 28 |
1 |
| 17 |
34143979 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. | 2021 Jul 12 |
1 |
| 18 |
34200245 | Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series. | 2021 Jun 7 |
1 |
| 19 |
34336608 | Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy. | 2021 |
1 |
| 20 |
34457184 | Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. | 2021 Sep |
1 |
| 21 |
34475104 | Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. | 2021 Nov 15 |
1 |
| 22 |
34572735 | Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance. | 2021 Sep 7 |
1 |
| 23 |
34680387 | Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing. | 2021 Oct 19 |
1 |
| 24 |
34681173 | Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells. | 2021 Sep 22 |
1 |
| 25 |
34722729 | Pancreatic Acinar Cell Carcinoma with Germline BRCA2 Mutation and Severe Pancreatic Panniculitis: A Case Report. | 2021 Oct |
1 |
| 26 |
34781271 | Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer. | 2021 Nov |
1 |
| 27 |
34900718 | Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. | 2021 |
1 |
| 28 |
34905798 | [Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review]. | 2021 Dec 14 |
1 |
| 29 |
35096857 | Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation. | 2021 |
1 |
| 30 |
31877465 | Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos. | 2020 Mar |
1 |
| 31 |
32041467 | Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug? | 2020 Jun |
1 |
| 32 |
32135515 | Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion. | 2020 Mar |
1 |
| 33 |
32249603 | Olaparib for advanced breast cancer. | 2020 Apr |
1 |
| 34 |
32555285 | Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. | 2020 Jun 18 |
1 |
| 35 |
32571788 | Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. | 2020 Sep 15 |
1 |
| 36 |
32764580 | Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties. | 2020 Aug 6 |
2 |
| 37 |
32778095 | Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. | 2020 Aug 10 |
1 |
| 38 |
32947941 | Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer. | 2020 Sep 16 |
1 |
| 39 |
32948057 | Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. | 2020 Sep 16 |
1 |
| 40 |
33152708 | Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. | 2020 Nov |
1 |
| 41 |
33261142 | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. | 2020 Nov 27 |
1 |
| 42 |
33271756 | Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells. | 2020 Dec 1 |
1 |
| 43 |
33283705 | [Effects and Mechanism of PARP Inhibitor Olaparib on the Expression of NKG2D Ligands in HL-60 Cells]. | 2020 Dec |
1 |
| 44 |
30348635 | The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity. | 2019 Mar 1 |
1 |
| 45 |
30660828 | Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. | 2019 Mar 1 |
1 |
| 46 |
30682083 | Synthetic lethality guiding selection of drug combinations in ovarian cancer. | 2019 |
1 |
| 47 |
30725116 | IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. | 2019 May |
1 |
| 48 |
30736840 | SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. | 2019 Feb 8 |
1 |
| 49 |
30833416 | Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. | 2019 Apr |
1 |
| 50 |
31031007 | Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. | 2019 Jun 13 |
1 |